| Primary |
| Fungal Infection |
11.5% |
| Aspergillosis |
11.4% |
| Bronchopulmonary Aspergillosis |
10.3% |
| Candidiasis |
10.1% |
| Pyrexia |
9.6% |
| Acute Myeloid Leukaemia |
6.0% |
| Sepsis |
5.5% |
| Systemic Candida |
5.5% |
| Prophylaxis |
4.6% |
| Antifungal Prophylaxis |
3.3% |
| Pneumonia |
3.3% |
| Evidence Based Treatment |
3.3% |
| Febrile Neutropenia |
2.5% |
| Immunosuppression |
2.3% |
| Infection |
2.1% |
| Transplant |
2.0% |
| Bacterial Infection |
1.8% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Hiv Infection |
1.6% |
| Septic Shock |
1.6% |
|
| Drug Ineffective |
23.8% |
| Septic Shock |
8.6% |
| Death |
8.4% |
| Sepsis |
6.3% |
| Systemic Candida |
5.8% |
| Fungal Infection |
4.9% |
| Renal Failure Acute |
4.9% |
| Respiratory Failure |
4.2% |
| Multi-organ Failure |
4.0% |
| Pancreatitis |
3.7% |
| Graft Versus Host Disease |
2.8% |
| Drug Resistance |
2.6% |
| Rash |
2.6% |
| Renal Failure |
2.6% |
| Toxic Epidermal Necrolysis |
2.6% |
| Treatment Failure |
2.6% |
| Zygomycosis |
2.6% |
| Organ Failure |
2.3% |
| Pyrexia |
2.3% |
| Transaminases Increased |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
19.6% |
| Pyrexia |
9.7% |
| Bronchopulmonary Aspergillosis |
9.0% |
| Drug Use For Unknown Indication |
8.9% |
| Sepsis |
7.3% |
| Acute Myeloid Leukaemia |
4.8% |
| Aspergillosis |
4.6% |
| Fungal Infection |
4.3% |
| Candidiasis |
4.1% |
| Transplant |
3.9% |
| Evidence Based Treatment |
3.8% |
| Systemic Candida |
3.6% |
| Prophylaxis |
3.1% |
| Septic Shock |
3.0% |
| Infection |
2.8% |
| Lung Infection |
1.7% |
| Febrile Neutropenia |
1.5% |
| Nausea |
1.5% |
| Pain |
1.5% |
| Bacterial Infection |
1.4% |
|
| Stevens-johnson Syndrome |
10.5% |
| Drug Ineffective |
10.1% |
| Toxic Epidermal Necrolysis |
9.1% |
| Renal Failure Acute |
6.4% |
| Transaminases Increased |
6.4% |
| Sepsis |
5.4% |
| Neuropathy |
5.1% |
| Septic Shock |
5.1% |
| Thrombocytopenia |
5.1% |
| Systemic Candida |
4.7% |
| Renal Tubular Disorder |
4.4% |
| Hepatocellular Injury |
3.7% |
| Respiratory Failure |
3.4% |
| Toxic Skin Eruption |
3.4% |
| Death |
3.0% |
| Gamma-glutamyltransferase Increased |
3.0% |
| Ventricular Fibrillation |
3.0% |
| Hepatitis |
2.7% |
| Renal Impairment |
2.7% |
| Treatment Failure |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
40.8% |
| Product Used For Unknown Indication |
22.5% |
| Diffuse Large B-cell Lymphoma |
13.3% |
| Pyrexia |
3.6% |
| Acute Myeloid Leukaemia |
2.5% |
| Hiv Infection |
1.9% |
| Prophylaxis |
1.7% |
| Infection Prophylaxis |
1.5% |
| Pneumonia |
1.4% |
| Infection |
1.3% |
| Graft Versus Host Disease |
1.2% |
| Cytomegalovirus Infection |
1.2% |
| Aspergillosis |
1.1% |
| Candidiasis |
1.0% |
| Haemolytic Uraemic Syndrome |
0.9% |
| Prophylaxis Against Graft Versus Host Disease |
0.9% |
| Antibiotic Therapy |
0.9% |
| Sleep Disorder |
0.8% |
| Renal Failure |
0.8% |
| Sarcoma Metastatic |
0.8% |
|
| Thrombocytopenia |
8.4% |
| Respiratory Failure |
7.9% |
| Septic Shock |
7.9% |
| Pneumonia |
7.3% |
| Sepsis |
6.7% |
| Venous Stent Insertion |
6.7% |
| Pyrexia |
6.2% |
| Febrile Neutropenia |
4.5% |
| Rash |
4.5% |
| Toxic Epidermal Necrolysis |
4.5% |
| Lactic Acidosis |
3.9% |
| Neutropenia |
3.9% |
| Renal Failure |
3.9% |
| Agranulocytosis |
3.4% |
| Blood Sodium Decreased |
3.4% |
| Death |
3.4% |
| Hepatosplenomegaly |
3.4% |
| Stenotrophomonas Infection |
3.4% |
| Torsade De Pointes |
3.4% |
| Toxoplasmosis |
3.4% |
|
| Interacting |
| Tuberculosis |
28.6% |
| Lung Transplant |
23.8% |
| Aspergillosis |
19.0% |
| Opportunistic Infection Prophylaxis |
11.9% |
| Antibiotic Prophylaxis |
7.1% |
| Bronchopulmonary Aspergillosis |
4.8% |
| Pulmonary Tuberculosis |
4.8% |
|
| Renal Failure Acute |
50.0% |
| Drug Interaction |
33.3% |
| Drug Level Increased |
16.7% |
|
